文献速递外周动脉疾病

准分子激光消融联合药物涂层球囊治疗慢性肢体威胁性缺血患者股腘动脉原发病变与支架内再狭窄的两年结局

Two-Year Outcomes of Excimer Laser Ablation Combined with Drug-Coated Balloon for Treating De Novo Lesions and In-Stent Restenosis in Femoropopliteal Artery of Chronic Limb-Threatening Ischemia Patients.
PubMed 文献 · Ann Vasc Surg · 2025-01-27

本回顾性单中心研究纳入2017年1月至2021年12月44例股腘动脉原发病变或支架内再狭窄的慢性肢体威胁性缺血患者,评估准分子激光消融联合药物涂层球囊的安全性和有效性。原发病变组24例、支架内再狭窄组20例,技术成功率均为100%,24个月一期通畅率原发病变组64.3%、支架内再狭窄组56.5%,主要不良事件发生率分别为12.5%和35%,差异均无统计学意义。

要点

  • 原发病变组24个月一期通畅率64.3%,支架内再狭窄组56.5%,差异无统计学意义(P=0.74)。
  • 原发病变组免于靶病变血运重建率24个月为85.4%,支架内再狭窄组为76.6%。
  • 主要不良事件发生率原发病变组12.5%、支架内再狭窄组35%,差异无统计学意义(P=0.27)。

核心结论

  • 对于包括长段闭塞和严重钙化在内的复杂病变,准分子激光消融联合药物涂层球囊在原发病变和支架内再狭窄病变中均显示高技术成功率和良好安全性。
  • 中期结局提示原发病变疗效可能优于支架内再狭窄病变的趋势。

研究设计与样本

  • 回顾性单中心分析,收集2017年1月至2021年12月的数据。
  • 纳入接受准分子激光消融联合药物涂层球囊治疗的股腘动脉原发病变和支架内再狭窄的慢性肢体威胁性缺血患者。
  • 共纳入44例患者,原发病变组24例,支架内再狭窄组20例。
  • 主要终点为24个月一期通畅率,次要终点包括技术成功率和主要不良事件(死亡、大截肢或靶血管血运重建)发生率。

主要发现

  • 患者平均年龄73.4±7.7岁,约三分之一合并慢性冠心病或脑血管病,约三分之一存在足部溃疡或坏疽,平均病变长度239.09±120.09 mm。
  • 原发病变组79.2%的病变为慢性完全闭塞,支架内再狭窄组75%的病变为Tosaka III型。
  • 两组技术成功率均为100%。
  • 原发病变组一期通畅率12个月为86.9%、24个月为64.3%,支架内再狭窄组分别为77.0%和56.5%。
  • 原发病变组免于靶病变血运重建率12个月为95.8%、24个月为85.4%,支架内再狭窄组分别为88.9%和76.6%;尽管支架内再狭窄组一期通畅率和免于靶病变血运重建率较低,差异无统计学意义(P=0.74)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: To evaluate the safety and efficacy of excimer laser ablation (ELA) combined with drug-coated balloon (DCB) in the treatment of chronic limb-threatening ischemia (CLTI) patients with de novo and in-stent restenosis (ISR) lesions in the femoropopliteal artery (FPA). METHODS: A retrospective, single-center analysis was performed on data collected between January 2017 and December 2021. The study included CLTI patients who underwent treatment with ELA combined with DCB for de novo and ISR lesions in the FPA. The primary endpoint was the 24-month primary patency rate. Secondary endpoints included technical success rate and the incidence of major adverse events (MAEs), defined as death, major limb amputation, or target vessel revascularization. RESULTS: A total of 44 patients were included in the study, comprising 24 cases in the de novo lesion group and 20 cases in the ISR group. The mean patient age was 73.4 ± 7.7 years, with approximately one-third presenting with concomitant chronic coronary artery disease (CAD) or cerebrovascular disease (CVD). Around one-third of the patients exhibited foot ulcers or gangrene, with a mean lesion length of 239.09 ± 120.09 mm. In the de novo lesion group, 79.2% of lesions were classified as chronic total occlusions (CTOs), whereas 75% of lesions in the ISR group were categorized as Tosaka III. For such complex lesions, the technical success rate was 100% in both groups. The primary patency rates for the de novo group were 86.9% at 12 months and 64.3% at 24 months, compared to 77.0% and 56.5% in the ISR group. Freedom from target lesion revascularization (TLR) rates in the de novo group were 95.8% and 85.4% at 12 and 24 months, respectively, while the ISR group achieved rates of 88.9% and 76.6%. Despite lower primary patency and freedom from TLR rates in the ISR group, the differences were not statistically significant (P = 0.74).MAE were observed in 12.5% of patients in the de novo group and 35% in the ISR group, with no statistically significant difference (P = 0.27). CONCLUSION: For CLTI patients with complex lesions, including extensive occlusions and severe calcification, the combination of ELA and DCB demonstrates high technical success and favorable safety profiles for both de novo and ISR lesions. Mid-term outcomes indicate a potential trend toward better efficacy in treating de novo lesions compared to ISR lesions.

来源:Ann Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Li Y, Tong Z, Guo J, et al. Two-Year Outcomes of Excimer Laser Ablation Combined with Drug-Coated Balloon for Treating De Novo Lesions and In-Stent Restenosis in Femoropopliteal Artery of Chronic Limb-Threatening Ischemia Patients. Ann Vasc Surg. 2025. PMID: 39864507. doi:10.1016/j.avsg.2025.01.016

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。